Cellivery Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cellivery Therapeutics's earnings have been declining at an average annual rate of -42.7%, while the Life Sciences industry saw earnings growing at 27.8% annually. Revenues have been growing at an average rate of 89.7% per year.
Key information
-42.7%
Earnings growth rate
-45.9%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 89.7% |
| Return on equity | n/a |
| Net Margin | -326.5% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cellivery Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 22,569 | -73,698 | 39,749 | 19,702 |
| 31 Dec 22 | 23,158 | -75,159 | 44,400 | 19,115 |
| 30 Sep 22 | 21,276 | -54,567 | 40,433 | 9,098 |
| 30 Jun 22 | 16,604 | -48,561 | 33,632 | 9,505 |
| 31 Mar 22 | 11,896 | -39,894 | 28,788 | 9,273 |
| 31 Dec 21 | 3,872 | -28,069 | 18,676 | 7,708 |
| 30 Sep 21 | 367 | -25,031 | 15,810 | 6,727 |
| 30 Jun 21 | 455 | -21,033 | 14,191 | 4,387 |
| 31 Dec 20 | 762 | -17,248 | 10,094 | 5,697 |
| 31 Dec 18 | 4,512 | -6,698 | 4,552 | 410 |
| 31 Dec 17 | 2,774 | -15,008 | 3,548 | 223 |
Quality Earnings: A268600 is currently unprofitable.
Growing Profit Margin: A268600 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A268600 is unprofitable, and losses have increased over the past 5 years at a rate of 42.7% per year.
Accelerating Growth: Unable to compare A268600's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A268600 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-2.2%).
Return on Equity
High ROE: A268600's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.